Rates of human papillomavirus vaccination increased for both boys and girls in the United States over the past decade, but remain below target levels and vary widely across states based on data from a nested cohort study including more than 7 million children.
"Understanding regional and temporal variations in HPV vaccination coverage may help improve HPV vaccination uptake by informing public health policy," Szu-Ta Chen, MD, of Harvard University, Boston, and colleagues wrote in Pediatrics.
To identify trends in one-dose and two-dose human papillomavirus (HPV) vaccination coverage, the researchers reviewed data from the MarketScan health care database between January 2003 and December 2017 that included 7,837,480 children and 19,843,737 person-years. The children were followed starting at age 9, when HPV vaccination could begin, and ending at one of the following: the first or second vaccination, insurance disenrollment, December 2017, or the end of the year in which they turned 17.
Overall, the proportion of 15-year-old girls and boys with at least a one-dose HPV vaccination increased from 38% and 5%, respectively, in 2011 to 57% and 51%, respectively, in 2017. The comparable proportions of girls and boys with at least a two-dose vaccination increased from 30% and 2%, respectively, in 2011 to 46% and 39%, respectively, in 2017.
Coverage Lacks Consistency Across States
However, the vaccination coverage varied widely across states; two-dose HPV vaccination coverage ranged from 80% of girls in the District of Columbia to 15% of boys in Mississippi. In general, states with more HPV vaccine interventions had higher levels of vaccination, the researchers noted.
Legislation to improve vaccination education showed the strongest association with coverage; an 8.8% increase in coverage for girls and an 8.7% increase for boys. Pediatrician availability also was a factor associated with a 1.1% increase in coverage estimated for every pediatrician per 10,000 children.
Cumulative HPV vaccinations seen among children continuously enrolled in the study were similar to the primary analysis, the Chen and associates said. "After the initial HPV vaccination, 87% of girls and 82% of boys received a second dose by age 17 in the most recent cohorts."
However, the HPV vaccination coverage remains below the Healthy People 2020 goal of 80% of children vaccinated by age 15 years, the researchers said. Barriers to vaccination may include a lack of routine clinical encounters in adolescents aged 11-17 years. HPV vaccination coverage was higher in urban populations, compared with rural, which may be related to a lack of providers in rural areas.
"Thus, measures beyond recommending routine vaccination at annual check-ups might be necessary to attain sufficient HPV vaccine coverage, and the optimal strategy may differ by state characteristics," they wrote.
The study findings were limited by several factors including the use of data from only commercially-insured children and lack of data on vaccines received outside of insurance, the researchers noted.
However, the results were strengthened by the large, population-based sample, and support the need for increased efforts in HPV vaccination. "Most states will not achieve the Healthy People 2020 goal of 80% coverage with at least two HPV vaccine doses by 2020," Chen and associates concluded.
Vaccination Goals Are Possible With Effort in the Right Places
The fact of below-target vaccination for HPV in the United States may be old news, but the current study offers new insights on HPV uptake, Amanda F. Dempsey, MD, PhD, of the University of Colorado at Denver, in Aurora, wrote in an accompanying editorial.
"A unique feature of this study is the ability of its researchers to study individuals over time, particularly at a national scope," which yielded two key messages, she said.
The longitudinal examination of vaccination levels among birth cohorts showed that similar vaccination levels were achieved more quickly each year.
"For example, among the birth cohort from the year 2000, representing 17-year-olds at the time data were abstracted for the study, 40% vaccination coverage was achieved when this group was 14 years old. In contrast, among the birth cohort from the year 2005, representing 12-year-olds at the time of data abstraction, 40% vaccination coverage was reached at the age of 12," Dempsey explained.
In addition, the study design allowed the researchers to model future vaccine coverage based on current trends, said Dempsey. "The authors estimate that, by the year 2022, the 2012 birth cohort will have reached 80% coverage for the first dose in the HPV vaccine series."
Dempsey said she was surprised that the models did not support the hypothesis that school mandates for vaccination would increase coverage; however, there were few states in this category.
Although the findings were limited by the lack of data on uninsured children and those insured by Medicaid, the state-by-state results show that the achievement of national vaccination goals is possible, Dempsey said. In addition, the findings "warrant close consideration by policy makers and the medical community at large regarding vaccination policies and workforce," she emphasized.The study received no outside funding. Chen had no financial conflicts to disclose. Several coauthors reported research grants to their institutions from pharmaceutical companies or being consultants to such companies. Dempsey disclosed serving on the advisory boards for Merck, Pfizer, and Sanofi Pasteur.
SOURCE: Chen S-T et al. Pediatrics. 2020 Sep 14. doi: 10.1542/peds.2019-3557.
This article originally appeared on MDedge.com, part of the Medscape Professional Network.
Medscape Medical News © 2020 WebMD, LLC
Send comments and news tips to email@example.com.
Cite this: HPV Vaccination Remains Below Healthy People Goals Despite Increases - Medscape - Oct 14, 2020.